
Drugmaker Insmed's INSM.O shares fall 1.6% to $82.45
Co forecasts 2025 revenue of $405 million to $425 million for their drug Arikayce, compared with analysts' expectations of $433 million as per data compiled by LSEG
Co reports Q4 revenue of $104.4 million, higher than analysts' est of $102.8 million, driven by Arikayce which is its only commercial drug
The drug is used for treatment of Mycobacterium avium complex (MAC) lung infections, which commonly affect individuals with weakened immune systems
Co reports Q4 loss of $1.32/share vs analyst est of $1.16/share loss
Stock has tripled in the past 12 months